Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Sarah L Buchan,Lang Dou,Marcus Remer,Steven G Booth,Stuart N Dunn,Chester Lai,Monika Semmrich,Ingrid Teige,Linda Mårtensson,Christine A Penfold,H T Claude Chan,Jane E Willoughby,C Ian Mockridge,Lekh N Dahal,Kirstie L S Cleary,Sonya James,Anne Rogel,Päivi Kannisto,Mats Jernetz,Emily L Williams,Eugene Healy,J Sjef Verbeek,Peter W M Johnson,Björn Frendéus,Mark S Cragg,Martin J Glennie,Juliet C Gray,Aymen Al-Shamkhani,Stephen A Beers
DOI: https://doi.org/10.1016/j.immuni.2018.09.014
IF: 32.4
2018-11-20
Immunity
Abstract:The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4-1BB enhance the proliferation and survival of antigen-stimulated T cells in vitro and promote CD8 T cell-dependent anti-tumor immunity in pre-clinical cancer models. We found that T regulatory (Treg) cells infiltrating human or murine tumors expressed high amounts of 4-1BB. Intra-tumoral Treg cells were preferentially depleted by anti-4-1BB mAbs in vivo. Anti-4-1BB mAbs also promoted effector T cell agonism to promote tumor rejection. These distinct mechanisms were competitive and dependent on antibody isotype and FcγR availability. Administration of anti-4-1BB IgG2a, which preferentially depletes Treg cells, followed by either agonistic anti-4-1BB IgG1 or anti-PD-1 mAb augmented anti-tumor responses in multiple solid tumor models. An antibody engineered to optimize both FcγR-dependent Treg cell depleting capacity and FcγR-independent agonism delivered enhanced anti-tumor therapy. These insights into the effector mechanisms of anti-4-1BB mAbs lay the groundwork for translation into the clinic.